Vorinostat, a Histone Deacetylase (HDAC) inhibitors, for instance, has been extensively studied in nanoparticle-based formulations [138, 139], demonstrating potential for enhanced drug delivery and efficacy against various cancer types. This evidence concerns the gene HDAC9 and cancer.